Research • Advancing what works in brain medicine

Research at Radial

Backed by research.
Driven by care.

Radial clinicians don't just follow the research, they conduct it. From neuromodulation to digital psychiatry, our team actively publishes and participates in clinical trials, ensuring every patient receives care that is grounded in the best available evidence.

Research areas

Movement Disorders

Schizophrenia Spectrum Disorders

Bipolar

Personality Disorders

OCD

PTSD

Anxiety

Depression

Publications

This is some text inside of a div block.

Scaling Psychedelic Therapies in the Health System

B Traux, E Marseille, Owen Muir, J Glastra

Psychedelic therapies are moving from clinical trials into health systems — but the infrastructure isn't ready. This report outlines the policy, training, and operational frameworks needed to integrate psychedelic-assisted treatment at scale.

This is some text inside of a div block.

Hourly mood assessments during accelerated rTMS for major depression: Trajectories of treatment response

Laura Schulze, Erica Nakano, Vivian Hoang, Kim Hoang, David Ling, Shan Siddiqi, Owen Muir, Nate Meng, Noah DeGaetano, Danielle DeSouza, David Carreon

When does relief actually begin during accelerated TMS — and can we track it hour by hour? This study used daily mood assessments to chart depression trajectories during treatment, revealing when and how quickly patients begin to respond.

This is some text inside of a div block.

Impact of accelerated intermittent theta-burst stimulation on anxiety symptoms in major depressive disorder

Erica Nakano, Vivian Hoang, Kim Hoang, Laura Schulze, David Ling, Shan Siddiqi, Owen Muir, Nathan Meng, Noah DeGaetano, Danielle DeSouza, David Carreon

Depression and anxiety often travel together — so how well does accelerated TMS address both? This trial found that accelerated theta-burst stimulation produced meaningful reductions in anxiety symptoms alongside its established antidepressant effects.

This is some text inside of a div block.

Cognitive changes and predictors of treatment outcome following accelerated rTMS treatment for depression

Kim Hoang, Laura Schulze, Erica Nakano, Vivian Hoang, David Ling, Shan Siddiqi, Owen Muir, Nate Meng, Noah DeGaetano, Danielle DeSouza, David Carreon

Can cognitive function predict who responds best to accelerated TMS? This study tracked cognitive changes before and after treatment, identifying baseline and post-treatment patterns that may help clinicians anticipate outcomes.

This is some text inside of a div block.

Mentalizing-Based Therapy for Borderline Personality Disorder and Other “Difficult” Patients"

Laurel L Williams, Carl Fleisher, Efrain Bleiberg, Owen S Muir, Chris Grimes, Robert A Dugger

Borderline personality disorder in adolescents is frequently misunderstood and undertreated. This paper applies Mentalizing-Based Therapy to emerging personality disorders in teens, offering a developmentally grounded framework for clinicians working with this population.

This is some text inside of a div block.

Basic Concepts in Mentalizing-Based Therapy for Emerging Personality Disorders

Laurel L Williams, Carl Fleisher, Owen S Muir, Chris Grimes, Carlene M MacMillan, Robert A Dugger

Personality difficulties in adolescence are often dismissed as a phase — but early intervention matters. This paper introduces core concepts of Mentalizing-Based Therapy for emerging personality disorders, equipping clinicians with a structured approach for younger patients.

This is some text inside of a div block.

Accelerated Dtms Utilization Of H7 Coil For Comorbid Trd: A Case Series

Aslam MacMillan, Carlene MacMillan, Owen Muir

Treatment-resistant depression with comorbidities demands more than standard protocols. This case series examines the use of accelerated dTMS with the H7 coil in complex patients, documenting outcomes that support its use in harder-to-treat presentations.

This is some text inside of a div block.

Real-world outcomes and predictors of accelerated rTMS treatment response for treatment-resistant depression

Danielle D DeSouza, Erica Nakano, Vivian Hoang, Kim Hoang, David Ling, Owen Muir, Nathan Meng, Noah DeGaetano, Shan H Siddiqi, David Carreon

Who responds to accelerated TMS in the real world — and what predicts success? This analysis of real-world treatment data identifies clinical and demographic factors associated with response, helping clinicians better match patients to this intensive protocol.

This is some text inside of a div block.

Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin

Burton J Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir

Psilocybin is arriving in clinical conversations faster than most primary care clinicians feel prepared for. This primer equips frontline providers with the evidence base, clinical context, and safety considerations needed to counsel patients meaningfully.

This is some text inside of a div block.

Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview

Burton J Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir

Psychedelic therapy didn't begin in research labs — it has a long, complex history worth understanding. This primer traces the historical foundations of psychedelic medicine, providing primary care clinicians with context for the current therapeutic renaissance.

This is some text inside of a div block.

Psychedelic therapy: a primer for primary care clinicians—ketamine

Viviana D Evans, Alejandro Arenas, Kenneth Shinozuka, Burton J Tabaac, Bryce D Beutler, Kirsten Cherian, Chelsey Fasano, Owen S Muir

Ketamine is already in primary care — but many clinicians lack a framework for its psychiatric applications. This primer covers mechanism, dosing, evidence, and patient selection, helping frontline providers engage knowledgeably with patients seeking this treatment.

This is some text inside of a div block.

Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)

Bryce D Beutler, Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir

LSD has re-entered serious clinical research after decades of prohibition. This primer gives primary care clinicians a grounded overview of current evidence, safety data, and therapeutic applications of lysergic acid diethylamide.

Learn more about our team